Form 4: Amgen Director Tyler Jacks Reports Acquisition of 809 Shares Through RSU Grant

Amgen Director Tyler Jacks reported the acquisition of 809 shares of common stock on May 23, 2025, through the vesting of Restricted Stock Units under the company's Director Incentive Program.

Summary

• Tyler Jacks, a Director at Amgen Inc. (AMGN), reported a change in beneficial ownership via a Form 4 filing.
• On May 23, 2025, Mr. Jacks acquired 809 shares of Amgen Common Stock.
• This acquisition was a grant (transaction price $0) related to Restricted Stock Units (RSUs) issued under the Amgen Inc. 2009 Director Incentive Program, as amended, and the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• The RSUs vested immediately and are paid in shares of the Company's common stock on a one-to-one basis.
• Following this transaction, Mr. Jacks beneficially owns a total of 17,193 shares of Amgen Common Stock.
• The total beneficial ownership includes 2,549 Dividend Equivalents (DEs) granted pursuant to the Director Program, which are credited on vested but deferred RSUs and paid out in shares on a one-to-one basis along with a cash payment for any remaining fractional share amount.

Sentiment

Score: 7

Explanation: The filing reports a routine insider transaction (RSU grant) which is a positive for aligning director and shareholder interests, but it does not contain new financial or operational news that would significantly alter the company's outlook or valuation.

Positives

• The acquisition of shares by a director through an RSU grant aligns the interests of management with those of shareholders, as the director's wealth is tied to the company's stock performance.
• The use of Restricted Stock Units (RSUs) as compensation is a common and effective method to incentivize long-term commitment and performance from board members.

Industry Context

This Form 4 filing details a routine insider transaction involving equity compensation for a director at Amgen Inc., a major biotechnology company. The practice of granting Restricted Stock Units (RSUs) and Dividend Equivalents (DEs) is a standard compensation mechanism across the pharmaceutical and biotechnology industries, designed to align the interests of board members with long-term shareholder value. Such filings are common disclosures for publicly traded companies.

Comparison to Industry Standards

• Equity-based compensation, specifically through RSU grants, is a widely adopted practice for compensating directors in large-cap biotechnology and pharmaceutical companies, consistent with global benchmarks.
• The structure, including immediate vesting and the provision for Dividend Equivalents, aligns with common corporate governance practices observed in companies like Pfizer, Johnson & Johnson, and Merck, which also utilize similar equity incentive programs for their board members to foster long-term alignment.

Corporate Governance

Related Party Transactions

• Acquisition of 809 shares by Director Tyler Jacks from Amgen Inc. through the vesting of Restricted Stock Units (RSUs) under the company's Director Incentive Program, which constitutes a related party transaction as it involves a company insider.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

Amgen, AMGN, Form 4, SEC filing, insider transaction, beneficial ownership, Restricted Stock Units, RSU, equity compensation, director compensation, Tyler Jacks